Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNYZ) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to 0.64.

  • Ligand Pharmaceuticals' Equity Ratio fell 2696.3% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year decrease of 2696.3%. This contributed to the annual value of 0.88 for FY2024, which is 96.45% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Equity Ratio is 0.64, which was down 2696.3% from 0.87 recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Equity Ratio high stood at 0.89 for Q2 2024, and its period low was 0.58 during Q1 2021.
  • For the 5-year period, Ligand Pharmaceuticals' Equity Ratio averaged around 0.78, with its median value being 0.8 (2023).
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 2462.59% in 2022, then tumbled by 2696.3% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Equity Ratio stood at 0.63 in 2021, then rose by 23.79% to 0.78 in 2022, then rose by 13.65% to 0.89 in 2023, then decreased by 0.96% to 0.88 in 2024, then fell by 27.03% to 0.64 in 2025.
  • Its last three reported values are 0.64 in Q3 2025, 0.87 for Q2 2025, and 0.88 during Q1 2025.